Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry
Business combination with Haymaker Acquisition Corp. III complete biote Corp.’s common stock will trade on the Nasdaq Stock Exchange under ticker symbol “BTMD” IRVING, TX, May 26, 2022 – biote Corp., (Nasdaq: BTMD) (“Biote” or […]
Haymaker Acquisition Corp. III Announces Stockholder Approval of Business Combination with Biote
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the […]
Haymaker Acquisition Corporation III Reminds Shareholders to Vote in Favor of the Proposed Business Combination with Biote Before May 24
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, reminds its shareholders to vote in favor of the […]
Biote Reports First Quarter 2022 Financial Results and Provides Corporate Update
Read Biote’s official press release on its Q1 2022 earnings now.
Biote Reports Record Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook
Read Biote’s official press release on its record earnings now.
Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III
BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”), a special purpose acquisition company, today announced that they have […]
Biote Announces Participation in ICR Conference 2022
Biote’s management team will participate virtually in the ICR Conference 2021.
Biote Recognized as 50-Fastest-Growing Women-Owned/Led Companies of 2021
Biote has been recognized as one of the 50 Fastest Women-Owned/Led Companies by The Woman Presidents’ Organization (WPO), in collaboration with JPMorgan Chase Commercial Banking, in their 14th annual ranking.
Dr. Mark Cone & Dana Jacoby Elected to Biote’s Board of Directors
Biote announced the appointments of Dr. Mark Cone and Dana Jacoby to the company’s Board of Directors. Cone and Jacoby bring six decades of combined experience in healthcare practice and business leadership to the […]
Largest Real-World Study of Bioabsorbable Testosterone Pellets in Men and Women Shows Low Complication Rates Over 7 Years and 1.2 Million Implants
Delivering testosterone via bioabsorbable pellets inserted under the skin is a low-risk approach to long-term hormone therapy for women and men, according to peer-reviewed data that Dr. Gary Donovitz, Biote founder, has published in […]
Study: Testosterone Pellet Therapy Reduces Breast Cancer Incidence in Women
A new study published by Biote founder Dr. Gary Donovitz, FACOG, and Mandy Cotten, DNP, APRN, FNP-C found that women who took testosterone via hormone pellets as part of bioidentical hormone replacement therapy (BHRT) […]